Journal
VACCINE
Volume 28, Issue 26, Pages 4249-4259Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.020
Keywords
Streptococcus pneumoniae; Serotype 19A; Pneumococcal conjugate vaccines
Categories
Funding
- Wyeth Pharmaceuticals, Collegeville, PA
- Wellcome Trust
- GlaxoSmithKline Pharmaceuticals
- Wyeth Ayerst-Lederle Pharmaceuticals
- Pfizer Inc
Ask authors/readers for more resources
Streptococcus pneumoniae serotype 19A is associated with all forms of pneumococcal disease and was the first reported pneumococcal serotype with high-level penicillin and multidrug resistance. While the seven-valent pneumococcal conjugate vaccine (PCV7), which contains serotype 19F, has reduced rates of disease among children and adults, the incidence of disease due to nonvaccine and increasingly drug-resistant serotypes - predominantly serotype 19A - has increased. This review summarizes the published literature to analyze the factors contributing to the emergence of serotype 19A, the diseases associated with this serotype, and the importance of including this serotype in novel pneumococcal conjugate vaccines. A recently approved 13-valent vaccine includes this serotype, and is likely to significantly reduce the burden of disease due to serotype 19A. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available